Ubiquitin specific peptidase 11 as a novel therapeutic target for cancer management

Area of Science:

• Biochemistry and Molecular Biology
• Oncology
• Cellular Biology

Background:

• Ubiquitination is a key post-translational modification regulating protein function, crucial in cellular processes like apoptosis, DNA damage response, and cell cycle progression.
• Deubiquitinases (DUBs) are enzymes that reverse ubiquitination, and their dysregulation is implicated in various cancers.
• Ubiquitin-specific peptidase 11 (USP11) is an emerging DUB with a complex role in cancer biology.

Purpose of the Study:

• To systematically review the multifaceted role of USP11 in the context of cancer-related pathways.
• To elucidate how USP11 influences the progression and chemoresistance of diverse cancer types.
• To discuss the therapeutic potential of targeting USP11 in cancer treatment strategies.

Main Methods:

• Systematic literature review of studies investigating USP11 function in cancer.
• Analysis of USP11's deubiquitinating activity on critical proteins within cancer signaling pathways.
• Comparative analysis of USP11's impact across different cancer types, including colorectal, breast, ovarian, and hepatocellular carcinomas.

Main Results:

• USP11 exhibits context-dependent roles, acting as either an oncogene or tumor suppressor in different cancers.
• USP11 deubiquitinates key proteins involved in cancer progression and chemoresistance mechanisms.
• Evidence suggests USP11 influences the efficacy of chemotherapy in various malignancies.

Conclusions:

• USP11 is a significant regulator of cancer development and progression through its modulation of protein ubiquitination.
• USP11's dual role highlights its complex involvement in oncogenesis and chemoresistance.
• Targeting USP11 presents a promising, albeit complex, therapeutic avenue for diverse cancers.